Baseline Characteristics of 88 Patients
| Characteristic | Value* |
| Age (y) | 71 (51–89)† |
| Time from diagnosis of mCRPC to 223Ra (mo) | 23 (0–87)† |
| ECOG performance status score | |
| 0 | 17 (19.3) |
| 1 | 68 (77.3) |
| 2 | 3 (3.4) |
| Extent of skeletal disease | |
| <6 metastases | 6 (6.8) |
| 6–20 metastases | 16 (18.2) |
| >20 metastases | 56 (63.6) |
| Superscan‡ | 10 (11.4) |
| BSI§ | 4.96 (0.1–35.4)† |
| Enlarged lymph nodes at baseline | 23 (26.1) |
| Previous use of cabazitaxel | 45 (51.1) |
| Previous use of docetaxel | 74 (84.1) |
| Previous lines of mCRPC therapy∥ | |
| 0 | 4 (4.5) |
| 1 | 13 (14.8) |
| 2 | 21 (23.9) |
| 3 | 40 (45.5) |
| 4 | 10 (11.4) |
| Biochemical values | |
| Total ALP, U/L | 152 (26–1,950)† |
| PSA, μg/L | 212 (3–3,441)† |
| LDH, U/L | 241 (138–2,330)† |
| Hemoglobin, mmol/L | 7.3 (5.1–9.1)† |
| Leukocytes, 109/L | 6.6 (3.3–13.0)† |
| Thrombocytes, 109/L | 254 (102–558)† |
↵* Values are reported as numbers of patients, with percentages in parentheses, unless otherwise indicated.
↵† Reported as median, with range in parentheses.
↵‡ Bone scintigraphy with diffuse skeletal uptake of tracer but without visible renal or background activity.
↵§ n = 87.
↵∥ Recorded mCRPC therapies included docetaxel, cabazitaxel, enzalutamide, and abiraterone.
ECOG = Eastern Cooperative Oncology Group.